Illumina’s Legal Triumph Limits EU Merger Control

Illumina Outmaneuvers EU's Merger Examination
BRUSSELS – The U.S.-based gene sequencing firm, Illumina, has successfully contested the European Union's review of its $7.1 billion acquisition of Grail, a maker of cancer diagnostic tests. This court victory signifies a notable limitation on the EU's authority over mergers that fall below its stipulated revenue threshold.